S
688373
vs
S
Shanghai Composite
Over the past 12 months, Shanghai MicuRx Pharmaceutical Co Ltd has underperformed Shanghai Composite, delivering a return of +4% compared to the Shanghai Composite's +22% growth.
Stocks Performance
688373 vs Shanghai Composite
Performance Gap
688373 vs Shanghai Composite
Performance By Year
688373 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Shanghai MicuRx Pharmaceutical Co Ltd
Glance View
Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 179 full-time employees. The company went IPO on 2022-08-05. The firm's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The firm also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The firm operates its businesses primarily in the domestic market.
